Helium One Global Ltd Announces Jackson-27 Flow Test Results & Gas Analysis Update
Highlights
Details
The Jackson-27 well reached TD at 1,183 feet (361m) within the Upper Lyons Formation, encountering the Lyons Sandstone Formation at 1,123 feet (342m). As expected, water was not encountered during drilling of the Lyons Formation with wireline logs confirming the penetrated Lyons Sandstone Formation to be high-quality and gas saturated.
Flow testing since TD has revealed increasing natural flow rates, reaching approximately 320 Mcfd to-date. Strong pressure build-up post-testing indicates high permeability and good reservoir communication. Based on previous engineering studies and observed flow rates, the projected stabilised flow rates constrained for production optimisation are expected to be between 350 Mcfd and 450 Mcfd, with a maximum of 550 Mcfd.
Initial laboratory analysis of gas samples from Jackson-27 showed a helium concentration up to 0.41% (air corrected) and 98.31% CO2 (and 1.27% nitrogen). The well has tested the far eastern extent of the Galactica project area, and understanding the flow potential and reservoir gas composition in this part of the field is key to defining the helium-CO2 development going forward.
Galactica/Pegasus Development
The Galactica project forms part of the broader Galactica/Pegasus development, discovered by Blue Star in 2022. This large-scale project offers multiple potential product streams. Blue Star is advancing the Galactica project in joint venture with Helium One Global Ltd.
Blue Star previously released results of an independent engineering analysis of wells in the Galactica-Pegasus project and this analysis established maximum stabilised rates and drawdown for development planning and economic modelling.
The analysis integrated results from the State-16 well with test data from the JXSN-1, JXSN-2, JXSN-3, and JXSN-4 discovery wells and compared it to public information from the adjacent Red Rocks development.
The study concluded:
o Calculated permeabilities in the JXSN discovery wells and State-16 well range from 300 millidarcies ('mD') to 750 mD
o This permeability range suggests initial flow rates at 6 pounds per square inch absolute ('psia') wellhead pressure of 334 Mcfd to 780 Mcfd
o The State-16 well showed a calculated permeability of 405 mD in the Upper Lyons Sandstone Formation, and stabilised initial flow rates constrained for production optimisation would be 250 Mcfd to 350 Mcfd with a maximum of 441 Mcfd
Development planning includes considering vacuum compression ranging from 11 psia (-1 pounds per square inch gauge ('psig')) to 6 psia (-6 psig) wellhead pressure which provides the ranges above.
The Jackson-27 well has shown a natural flow rate of approximately 320 Mcfd which compares favourably to the State-16 well which showed a sustained natural flow rate of 150 Mcfd.
Given the higher natural flow at Jackson-27, due to greater permeability in the high-quality Upper Lyons Sandstone Formation, and the previous independent engineering study, projected potential stabilised flow rates, constrained for production optimisation, are expected to be 350 Mcfd to 450 Mcfd with a maximum potential rate of 550 Mcfd.
For further information please visit the Company's website: www.helium-one.com
Contact
Notes to Editors
Helium One Global, the AIM-listed Tanzanian explorer, holds prospecting licences across two distinct project areas, with the potential to become a strategic player in resolving a supply-constrained helium market.
The Rukwa and Eyasi projects are located within rift basins on the margin of the Tanzanian Craton in the north and southwest of the country. These assets lie near surface seeps with helium concentrations ranging up to 10.4% helium by volume. All Helium One's licences are held on a 100% equity basis.
The Company's flagship southern Rukwa Project is located within the southern Rukwa Rift Basin in south-west Tanzania. This project is considered to be entering an appraisal stage following the success of the 2023/24 exploration drilling campaign, which proved a helium discovery at Itumbula West-1 and, following an extended well test, successfully flowed 5.5% helium continually to surface in Q3 2024.
Following the success of the extended well test, the Company flowed significant quantities of helium to surface and filed a Mining Licence ('ML') application with the Tanzania Mining Commission in September 2024. The 480km2 ML has now been offered to the Company and was officially accepted in March 2025.
The Company also owns a 50% working interest in the Galactica-Pegasus helium development project in Las Animas County, Colorado, USA. This project is operated by Blue Star Helium Ltd (ASX: BNL).
Helium One is listed on the AIM market of the London Stock Exchange with the ticker of HE1 and on the OTCQB in the United States with the ticker HLOGF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Helium One Global Ltd
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
OneMain Financial: What to Know Before Taking Out a Rent Loan
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / When money is tight, and rent is due, some people may look for quick solutions to stay in their homes. Rent loans are one option that could help in tough times. A rent loan provides a borrower with a lump sum of money to cover rent when they don't have enough money saved up. While rent loans might offer quick help, it's important to understand how they work and what to expect before applying. Understand the ins and outs of a rent loan A rent loan is a type of personal loan that helps a renter pay their housing costs if they don't have enough money in the bank. First, the consumer borrows a predetermined amount of money and will then typically pay it back over a set period of time by making fixed monthly payments. Each payment covers two parts of the loan. First is the loan principal, which is the original amount that's borrowed, and second is interest, which is the cost of borrowing. Qualified borrowers can apply for rent loans through different types of lenders, including online lenders, banks or credit unions. To get approved, the borrower typically needs a steady income and a favorable credit score - though eligibility requirements vary by lender. Consider a rent loan a quick fix, not a long-term solution A rent loan may help someone when money is tight, but it's not meant to solve long-term financial problems. A rent loan is a temporary solution that should only be used when there's a clear plan to repay it. For example, if someone is between jobs and has new employment starting soon, a rent loan might help bridge the gap. Similarly, if they're waiting on a delayed paycheck or emergency funds, the loan could help them stay on track. But if they don't know when they'll have a steady income again, taking out a loan could cause more harm than good. If a renter ends up needing to take out a rent loan every month just to stay afloat, it may be time to look for other types of help. Different types of financial support could include government assistance or even working out a payment plan with their landlord. Be mindful of any additional fees attached to the loan When taking out a rent loan, the interest rate isn't the only cost. There might be extra fees that result in making the loan more expensive. These might include: All these charges can increase the total cost of the loan. That's why it's important to ask questions and consider all the financial obligations before signing any loan agreement documents. Budgeting for monthly repayments is key It's important for someone to make sure they can repay a rent loan with interest in the given repayment period before they sign on the dotted line. Taking the time to calculate all monthly bills, including groceries, utilities, commuting costs and other regular expenses, and figuring out how a loan repayment fits in, could go a long way to helping someone avoid coming up short and worrying they will never catch up. Making monthly rent loan payments on time and in full may protect the borrower's credit score - but only as long as their other bills stay current too, because late or missed payments could damage the credit score. While a rent loan can help lower financial stress in the short term, it's important to make sure taking on debt doesn't add stress in the long term. Extra debt can be hard to manage without a clear plan for how it fits into someone's overall budget. A renter should make the best choice for their situation Rent loans can help in a tight spot, but they come with real costs. Before taking out a loan, it's important to look at the full picture - how much it will cost, how it will be repaid, how long it will take to be repaid, and whether other options are available. With careful planning and smart choices, it may be possible to stay on top of rent without falling deeper into debt. About OneMain Financial View Website OneMain Financial is the leader in offering nonprime customers responsible access to credit and is dedicated to improving the financial well-being of hardworking Americans. CONTACT: Sonakshi Murze Manager [email protected] SOURCE: OneMain Financial press release
CNBC
a day ago
- CNBC
From Starbucks to Smoothie King, restaurants seek to cash in on consumers' protein frenzy
Restaurant chains are joining in on the protein frenzy, hoping to encourage diners to pay more for extra macronutrients during a time when many consumers aren't spending as much. From "gym bros" to users of GLP-1 drugs like Ozempic, many Americans are trying to add more protein to their diets, with the goal of building or maintaining their muscle mass and feeling more satiated after meals. Moreover, diet trends that don't emphasize protein intake, such as the ketogenic diet, have fallen out of favor. "A lot of younger consumers are more proactive about their health habits, so they're looking for ways to support health now but also to support their health in the future," said Julia Mills, a food and drink analyst for market research firm Mintel. "Generation Alpha, Gen Z, millennials — these consumers are very active on social media, so they're constantly being fed this message that you need more protein, and protein helps you gain muscle and makes you stronger." Roughly a third of consumers said they loved high protein in the second quarter of 2025, up from 24% three years ago, according to Datassential, which tracks restaurant menus and consumer preferences. The trend has fueled a protein takeover in grocery store aisles, from protein-packed Eggo waffles to Khloe Kardashian's Khloud protein popcorn. But it's also hitting the menus of restaurants that are seeking ways to encourage diners to pay for premium food and drinks. Take Starbucks, for example. The coffee giant said in late July that it will roll out a cold foam packed with 15 grams of protein later this year; the regular cold foam add-on typically costs customers an extra $1.25 per drink. The new foam comes as the chain's U.S. sales have been shrinking for the past year as coffee drinkers brew their java at home or seek out trendier options. Rival Dutch Bros launched a protein coffee in early 2024 and charges customers an extra $1 for the customization. The menu addition fueled strong same-store sales growth and profits for the upstart chain. Eateries are seeking to attract diners like Jared Hutkowski, a 42-year-old director of brokerage in Harrisburg, Pennsylvania. He works out six days a week and tries to hit his daily protein goal to improve his physique and overall health. When he dines out, he tries to maximize his protein, although he sometimes goes for pizza anyway. "The biggest factor is what I am in the mood for that day, and then I normally try and select a meal that has a least a serving of some type of protein in it," Hutkowski said. This year, 28.4% of U.S. restaurant menus call out "protein," up from 5.9% a decade ago, according to Datassential. And the trend looks like it has staying power. Datassential predicts that by 2029, more than 40% of eateries will highlight protein on their menus. "Protein is one of those things that's never been vilified, because no one's ever said that eating too much protein can be bad for you," Mintel's Mills said. In the short term, consuming more protein than your body needs likely won't cause health issues, but in the long term, it could cause kidney problems, according to Diane Han, a registered dietitian based in San Francisco and the founder of Woking Balance Wellness. The recommended daily amount of protein intake varies by body weight but is roughly 46 grams for women and 56 grams for men, according to the Centers for Disease Control and Prevention. For restaurants, protein's step change happened several years ago. In 2021, protein only had a menu penetration of 11.5%; by 2022, more than a quarter of restaurant menus used the term, based on Datassential data. That year, Dine Brands' IHOP, for example, introduced pancakes with 18 grams of protein per flapjack. Fast-casual eateries are the restaurant segment most likely to call out protein on their menus, thanks to the common practice of asking customers to pick their protein or offering to double their portion, according to Datassential. Fast-casual salad chain Sweetgreen introduced a line of "protein plates" in late 2023 as part of an effort to introduce more hearty options for dinner customers. The menu addition has helped the company grow its dinner business from 35% of sales to about 40%, executives said in March. Many restaurants are also leaning into U.S. consumers' desire for convenience. Accessibility may be why Datassential found that consumers tend to prefer protein-packed beverages. For Smoothie King, protein has been a menu staple since its founding more than 50 years ago. But in October, the chain took one step further, launching a menu aimed at consumers who take GLP-1 drugs for weight loss or diabetes. The rapid weight loss that can occur from the medications can cause muscle mass to drop, so doctors often advise patients to increase their protein intake to maintain their muscle. "It's a convenient, on-the-go way to get in your protein that you're looking for in your diet," said Lori Primavera, Smoothie King's vice president of research and development and product marketing. Many restaurants are also choosing to highlight existing protein-packed options, rather than adding new menu items that would slow down kitchens or add to much complexity to their operations. For example, Panda Express introduced its own protein plates earlier this year. The line, created in partnership with a registered dietitian, includes pre-existing menu items but packages them as a balanced meal, highlighting protein and fiber content. Chipotle Mexican Grill employed a similar strategy back in 2019 when it introduced "lifestyle bowls," marketed to fit different dietary goals, like the paleo diet or offering double protein. Likewise, in July, Chick-fil-A put the spotlight on its own high-protein options in a company blog, highlighting its grilled nuggets and the Cool Wrap, which features a grilled chicken breast, cheese and lettuce in a tortilla. But for the eateries that want to add new menu items, nachos with a choice of protein, restaurant-made protein bars and egg dishes that highlight high protein content are all increasingly popular options, according to Datassential trendologist Claire Conaghan. Eggs are one reason why breakfast, brunch and lunch eatery First Watch has always been "protein forward," CEO Chris Tomasso told CNBC. The chain hasn't adjusted its menu specifically to address consumers' demand for more protein, but TikTok influencers have highlighted how to order a high-protein meal when visiting its restaurants. "We hope that continues to be a trend because we're right down the middle of the fairway on that," Tomasso said. Of course, protein isn't the only way to win over health-conscious consumers. Hutkowski said his primary issue with eating at restaurants is that most of the food is cooked in oils, butter and heavy greases that rapidly add to his intake of fats for the day. "A restaurant finding cleaner ways to cook would be much more attractive to me than overly loaded protein dishes," he said.
Business Insider
a day ago
- Business Insider
How Wall Street Missed the Bigger Picture on Novo Nordisk Stock (NVO)
Once seemingly unstoppable, Novo Nordisk (NVO) stock is now caught in a storm. Fierce competition in the GLP-1 space—especially from cheaper compounders—has taken a toll on its U.S. market share, and there's growing skepticism around the strength and pace of its growth story. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. To turn things around, investors are now hanging hopes on favorable litigation outcomes and smart pricing decisions that can protect margins and help the company reclaim lost ground, all while delivering on its now more conservative guidance. The bright side, though, is that Novo Nordisk still maintains rock-solid fundamentals: its profit margins lead the pack, cash flow generation is healthy, and it trades at what looks like de-risked multiples, backed by one of the best balance sheets in the sector — second only to Johnson & Johnson (JNJ). Given this disconnect between strong fundamentals and the market's bearish mood, I rate NVO as a Buy. Still, the stock could remain under pressure in the short to mid-term as the market struggles to price in the uncertainty tied to the ongoing litigation mess. Why Novo Nordisk is Under Pressure Novo Nordisk went from heaven to hell in about two years, soaring 110% from $63 per share in 2023 to over $140 by mid-2024, only to then plunge 66% down to below $50. The stars of the show were Ozempic and Wegovy, which made Novo Nordisk a leader in the obesity drug market. But Novo Nordisk started losing ground as competitors, especially Eli Lilly (LLY) with Mounjaro and Zepbound, came onto the scene—both showing clinical results with even greater weight loss than Ozempic and Wegovy. This competition hit Novo's top line hard, slowing revenue growth from 35% in 2023 to 17.3% in 2024, while operating income growth dropped from 42% to 25.3% over the same period. Recently, Novo Nordisk lowered its 2025 outlook, now expecting revenue growth only in the mid-single digits and operating profit growth between 10% and 16%. That's a major slowdown compared to the heady days fueled by Ozempic and Wegovy. The U.S. market remains the primary source of weakness, with growth slowing sharply compared to international markets, which are still on the rise. On the bright side, Novo still expects over $5.8 billion in free cash flow for 2025, showing a resilient core business. That translates to a forward FCF yield of about 3.5% today—well above Eli Lilly's current 0.5% yield—suggesting a fairly competitive valuation despite the pressures from compounders. And the patient base behind it all is real and solid. NVO's Compounder Problem and Legal Battles Speaking of compounders, this has been Novo Nordisk's biggest headache in its U.S. operations. The company has been hit hard by unauthorized compounder versions of its GLP-1 drugs, sold through alternative providers like Hims & Hers (HIMS) at lower prices, stealing market share—especially among more price-sensitive customers. It's important to note that Hims & Hers, once a distribution partner for Novo Nordisk, isn't selling FDA-approved generics, but instead is exploiting a legal loophole called the compounding pharmacy exception. This allows pharmacies to create injectable versions when there's a shortage of the original product, which has been the case for Wegovy and Ozempic. So, the situation is a bit murky but not exactly illegal. At least not yet. Novo Nordisk hasn't been sitting still and has taken legal action to shut down these compounders. But progress has been slow, and because of the uncertainty around how this will play out, management hasn't given clear guidance for 2026. And as we know in the stock market, uncertainty often hurts more than bad news, so NVO stock has taken a hit. The Opening Act of Novo Nordisk's Market Fight If this dispute ends in Novo Nordisk's favor, there's a lot on the table. Estimates suggest that around one million patients in the US are currently using compounded GLP-1 drugs. If these are removed from the market, as many as three-quarters could shift to branded options—though Novo might only capture a third of that. Still, even that slice would represent a major tailwind for the company moving forward. The tricky part is that regulators seem reluctant to take cheaper GLP-1 alternatives off the market. That puts Novo Nordisk in a tough spot—potentially needing to cut prices (and eat into margins) just to make regulators more comfortable, hoping to make up for it later by regaining market share. On a brighter note, Novo recently scored a big win: its obesity drug is now the only GLP-1 included in CVS's (CVS) national coverage template, which should boost both volume and visibility. While Lilly's Zepbound is, on average, more effective than Wegovy, drug superiority isn't the only factor that determines market dominance. Side effects and, just as importantly, distribution channels play a huge role in driving adoption. A Quality Name at a Discount Considering Novo Nordisk is still growing revenue at double-digit rates, has a 3.3% dividend yield, and maintains net profit margins of 34.5% —around 12% higher than Eli Lilly's and arguably better than any other major biotech—the market's reaction to its guidance cut seems somewhat overdone. The stock is trading at just 11.6x forward earnings and 11x cash flows—roughly 30% and 21% below the industry average, respectively. That looks like a discount that might not be entirely justified for a company that, while facing some headwinds and slowing growth, has consistently delivered strong financials and now seems to be trading at heavily de-risked multiples. What is the Forecast for NVO Stock? On Wall Street, NVO stock carries a Moderate Buy consensus rating based on two Buy, three Hold, and zero Sell ratings over the past three months. NVO's average stock price target of $73 implies almost 50% upside potential over the next twelve months. Battling Compounders on the Road to Recovery Novo Nordisk is now in a position where it needs to prove it can sustain healthy growth despite competition from lower-priced compounders, while also expanding its share in the massive and growing obesity treatment market. The sluggish momentum from its highs and the recent earnings update, which lowered its annual guidance, have naturally pushed the market to revise its growth expectations downward. The investment case depends on the results of ongoing litigation, pricing strategies, and regulatory decisions, all of which will help clarify the path for future growth. But even with growth slowing, the fundamentals remain solid—margins are better than peers', and the stock trades at valuations that feel sufficiently de-risked. For long-term investors, it looks like a good buying opportunity.
